Skip to main content
. 2021 Dec 9;11(12):1371. doi: 10.3390/life11121371

Figure 2.

Figure 2

TYMS upregulation of visfatin induction attenuates the sensitivity of human DLD-1 CRC cells to capecitabine cytotoxicity. (A) Human DLD-1 CRC cells were pretreated with vehicle (PBS) or visfatin (50 ng/mL) for 1 h and then kept as control or treated with capecitabine (2.5, 5, and 10 μM) for 24 h. (B) Human DLD-1 CRC cells were transfected with control- or TYMS-specific siRNA (si-TYMS) for 48 h and then pretreated with vehicle (PBS) or visfatin (50 ng/mL) for 1 h and further kept as control or treated with capecitabine (CAP, 5 μM) for 24 h. (A,B) The viability of treated cells was examined by MTT assay. Data were shown as mean ± SEM from three independent experiments. p < 0.05 was indicated as statistically significant.